CA2661547A1 - Solid dosage form - Google Patents

Solid dosage form Download PDF

Info

Publication number
CA2661547A1
CA2661547A1 CA002661547A CA2661547A CA2661547A1 CA 2661547 A1 CA2661547 A1 CA 2661547A1 CA 002661547 A CA002661547 A CA 002661547A CA 2661547 A CA2661547 A CA 2661547A CA 2661547 A1 CA2661547 A1 CA 2661547A1
Authority
CA
Canada
Prior art keywords
particles
dosage form
solid dosage
coating
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002661547A
Other languages
English (en)
French (fr)
Inventor
Peter Persicaner
Craig Judy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrow International Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2661547A1 publication Critical patent/CA2661547A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3865—Polyphosphonic acids containing sulfur substituents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002661547A 2006-08-24 2007-08-24 Solid dosage form Abandoned CA2661547A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0616794.4A GB0616794D0 (en) 2006-08-24 2006-08-24 Solid dosage form
GB0616794.4 2006-08-24
PCT/GB2007/003224 WO2008023184A2 (en) 2006-08-24 2007-08-24 Solid dosage form

Publications (1)

Publication Number Publication Date
CA2661547A1 true CA2661547A1 (en) 2008-02-28

Family

ID=37102775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002661547A Abandoned CA2661547A1 (en) 2006-08-24 2007-08-24 Solid dosage form

Country Status (9)

Country Link
US (3) US8697124B2 (OSRAM)
EP (1) EP2054038A2 (OSRAM)
JP (1) JP2010501538A (OSRAM)
AU (1) AU2007287365B2 (OSRAM)
BR (1) BRPI0714360A2 (OSRAM)
CA (1) CA2661547A1 (OSRAM)
GB (1) GB0616794D0 (OSRAM)
NZ (1) NZ574798A (OSRAM)
WO (1) WO2008023184A2 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
SG188509A1 (en) * 2010-09-13 2013-04-30 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
FI126168B (en) 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
EP3419659A1 (en) 2016-02-23 2019-01-02 The Regents of the University of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
CN106631735B (zh) * 2016-12-03 2023-10-20 湖北泰盛化工有限公司 一种多聚甲醛再解聚的系统及其方法和应用
KR102496427B1 (ko) 2018-01-16 2023-02-06 어플라이드 머티어리얼스, 인코포레이티드 금속 산화물로 캡슐화된 약물 조성물들 및 그의 제조 방법들
WO2021041673A1 (en) 2019-08-27 2021-03-04 Applied Materials, Inc. Vapor phase coating technology for pharmaceutical abuse deterrent formulations
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
TWI870622B (zh) 2020-10-02 2025-01-21 美商應用材料股份有限公司 製備氧化矽塗佈藥品的低溫處理
WO2023056304A1 (en) 2021-09-30 2023-04-06 Applied Materials, Inc. Low temperature silicon oxide coating for pharmaceutical applications

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122479C (en) 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5431920A (en) 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
FI94926C (fi) * 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
TW390813B (en) 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
RU2193880C2 (ru) * 1997-06-11 2002-12-10 Дзе Проктер Энд Гэмбл Компани Покрытая пленкой таблетка улучшенной безопасности для верхних отделов желудочно-кишечного тракта
SE9703691D0 (sv) 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
FR2781793B1 (fr) * 1998-08-03 2001-07-20 Prographarm Lab Procede de fabrication de granules de gabapentine enrobes
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
US6740341B1 (en) * 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
SE9901272D0 (sv) 1999-04-09 1999-04-09 Astra Ab New improved formulation
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
AU2127200A (en) 1999-11-02 2001-05-14 Cipla Limited A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
PL196485B1 (pl) 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
US6350471B1 (en) * 2000-05-31 2002-02-26 Pharma Pass Llc Tablet comprising a delayed release coating
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1490031A1 (en) * 2002-03-07 2004-12-29 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US20040138180A1 (en) 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US6781011B2 (en) * 2002-12-13 2004-08-24 Texas Christian University Bis-H-phosphinic acid derivatives as precursors to therapeutic bisphosphonates and uses thereof
EP1596870B2 (en) 2002-12-20 2011-04-06 F. Hoffmann-La Roche AG High dose ibandronate formulation
CA2520321A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
CA2559670A1 (en) * 2003-04-14 2004-10-28 Gabor Pragai Stable amlodipine maleate formulations
GR1004660B (el) 2003-06-25 2004-08-25 ������������, �������� ��� ����������� �������� �������� ��� �.�. ��������-������������ �.�. Βελτιωμενες φαρμακευτικες συνθεσεις του τριυδρικου αλενδρονικου νατριου και μεθοδοι παρασκευης τους
EP1680092A2 (en) * 2003-09-29 2006-07-19 Cipla Ltd. Pharmaceutical formulation with improved stability
GB0330255D0 (en) 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
CA2555406A1 (en) 2004-02-19 2005-09-01 Teva Pharmaceutical Industries, Ltd. Improved therapy using a combination of raloxifene and alendronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
EP1781258A1 (en) 2004-08-20 2007-05-09 Mepha AG Formulations of bisphosphonates
WO2006046100A1 (en) 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Pharmaceutical composition of alendronic acid
AU2005309601A1 (en) * 2004-11-23 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such NMDA antagonist to a subject
WO2006100527A1 (en) * 2005-03-24 2006-09-28 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Effervescent tablet containing sodium alendronate and related use and process

Also Published As

Publication number Publication date
WO2008023184A3 (en) 2008-04-24
US8697124B2 (en) 2014-04-15
US10420725B2 (en) 2019-09-24
NZ574798A (en) 2012-02-24
AU2007287365B2 (en) 2012-06-07
GB0616794D0 (en) 2006-10-04
JP2010501538A (ja) 2010-01-21
EP2054038A2 (en) 2009-05-06
AU2007287365A1 (en) 2008-02-28
BRPI0714360A2 (pt) 2013-04-24
US20140220128A1 (en) 2014-08-07
US20090317460A1 (en) 2009-12-24
US20160030358A1 (en) 2016-02-04
WO2008023184A2 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
US10420725B2 (en) Solid dosage form of coated bisphosphonate particles
KR100496086B1 (ko) 비스포스포네이트를 포함하는 경구 투여용 약학 조성물의 제조 방법
CN1124130C (zh) 含氯甲双磷酸盐活性成分和硅化微晶纤维素赋形剂的药物制剂
JP5037746B2 (ja) イバンドロネートを含む経口薬理製剤
CN1649598B (zh) 高剂量伊班膦酸制剂
WO2009018834A1 (en) Pharmaceutical composition containing bisphosphonate and method for the preparation thereof
JP6374879B2 (ja) 骨粗しょう症治療用の安定な医薬組成物
EP1617826B1 (en) The dispersible alendronate microparticle formulation
EP1491199B1 (en) Pharmaceutical compositions of alendronate sodium trihydrate and process for the preparation thereof
MXPA01003407A (en) Process for the preparation of oral pharmaceutical compositions comprising biphosphonates
MXPA06009804A (en) Pharmaceutical compositions comprising bisphosphonates and vitamins weekly and fortnightly administered
MX2007014056A (es) Composicion farmaceutica solida para administracion oral de acido ibandronico o una sal o un hidrato farmaceuticamente aceptable del mismo, procedimiento de preparacion de dicha composicion mediante compresion directa, formulaciones farmaceuticas que
AU2006222690A1 (en) High dose ibandronate formulation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20140826